TableĀ 2

Weighted proportions of participants reporting AEs for those using prescription drugs, NHPs or both, by pharmacy and province

PharmacyParticipants reporting AE (ni)Prescription drug use AEs (np) (pp)NHP use only AEs (nn) (pn)Concurrent use AEs (nc) (pc)
AB0150 (0.0%)0 (0.0%)5 (6.9%)
AB0281 (3.0%)1 (11.1%)6 (8.0%)
AB03102 (6.3%)0 (0.0%)8 (12.5%)
AB04191 (1.4%)0 (0.0%)8 (8.1%)
AB0530 (0.0%)0 (0.0%)3 (60.0%)
AB0650 (0.0%)0 (0.0%)5 (4.7%)
AB0731 (6.3%)0 (0.0%)2 (8.7%)
Alberta total535 (1.9%) (95% CI 0.8 to 4.4)1 (3.0%) (95% CI 0.4 to 18.6)47 (8.3%) (95% CI 6.3 to 10.8)
BC0100 (0.0%)0 (0.0%)0 (0.0%)
BC0210 (0.0%)0 (0.0%)1 (4.0%)
BC0300 (0.0%)0 (0.0%)0 (0.0%)
British Columbia total10 (0.0%)0 (0.0%)1 (1.1%) (95% CI 0.2 to 7.5)
Western Canada total545 (1.2%) (95% CI 0.51 to 2.9)1 (2.7%) (95% CI 0.4 to 16.9)48 (7.3%) (95% CI 5.6 to 9.6)
  • AEs, adverse events; NHPs, natural health products.